Synapse Te E Gyan May 19

Nicerbium is used in the treatment of Dementia of Alzheimer's type. This means that it is specifically prescribed for individuals who have been diagnosed with Alzheimer's disease, a progressive neurological disorder that affects memory, thinking, and behavior. Nicerbium may help to improve cognitive function and slow down the progression of the disease in these patients. It is not used for treating diabetes, anxiety, or hypertension.

The brand positioning "Brightens mood brightens life" suggests that Versidep NF is a product that improves mood and enhances overall quality of life. This positioning implies that using Versidep NF can have a positive impact on one's emotional well-being, potentially uplifting their spirits and improving their overall outlook on life.

Escitalopram belongs to the class of drugs known as selective serotonin reuptake inhibitors (SSRIs). SSRIs work by increasing the levels of serotonin, a neurotransmitter, in the brain. This helps to improve mood and relieve symptoms of depression and anxiety. Escitalopram specifically inhibits the reuptake of serotonin, allowing it to remain in the brain for longer periods of time and enhancing its effects. Therefore, the correct answer is SSRI.

Nicergoline is a medication that is known to block the Alpha 1 adrenoreceptor. This receptor is found in various tissues and plays a role in regulating blood pressure by causing vasoconstriction. By blocking this receptor, Nicergoline can help to dilate blood vessels and improve blood flow. It is commonly used in the treatment of conditions such as Raynaud's disease and dementia.

The correct answer is "All of the above" because Nicerbium needs to be promoted to all neurologists, all neurosurgeons, and psychiatrists. This implies that Nicerbium is relevant and beneficial for all these medical professionals and their respective fields of expertise.

The correct answer is 200 Mcg. This is the amount of chromium present in Nurica BT.

Nicerbium shows positive effects on both cognition and behavior. This means that it has beneficial effects on both mental processes such as thinking, memory, and attention (cognition), as well as actions and responses (behavior).

The correct answer is 30 mg BID for six months. This means that the recommended dose of Nicerbium is 30 mg taken twice a day for a duration of six months. This dosing regimen ensures that the patient receives a consistent amount of the medication throughout the day, providing optimal therapeutic effects. Taking the medication twice a day also helps to maintain steady blood levels of the drug, maximizing its efficacy and minimizing potential side effects.

The punch line "An assurance of better pain control" suggests that Nurica NT is a product that guarantees effective pain management. This implies that Nurica NT is specifically designed to provide relief from pain and is marketed as a solution for individuals seeking improved pain control. The other options, Nurica BT and Nurica M, are not mentioned in relation to pain control, making Nurica NT the most suitable choice based on the given information.

The correct answer is Teva Pharmaceuticals Israel. This suggests that Teva Pharmaceuticals Israel is the source of the raw material for Nicergoline.

The statement suggests that in order to earn call average, compliance, and RCPA Norms incentive, there should not be negative growth. Additionally, the disbursement will be done quarterly according to the reporting schedule set by the company. Therefore, the answer is true.

Nicergoline is a medication that is known to have multiple effects on the body. It has been found to increase the utilization of glucose, which is an important source of energy for cells. Additionally, it also enhances the utilization of oxygen, which is crucial for various metabolic processes. Therefore, the correct answer is "All of the above" as nicergoline increases the utilization of both glucose and oxygen.

The Neptune Trial is a clinical trial that evaluated the efficacy of Pregabalin. This trial provided evidence and data to support the effectiveness of Pregabalin in treating a specific condition or symptom. The endorsement of Pregabalin's efficacy by the Neptune Trial indicates that the trial results showed positive outcomes and supported the use of Pregabalin for the intended purpose.

The given answer states that Pregabalin is a Level A Drug. According to the information provided, Pregabalin is recommended as a Level A Drug for the treatment of PDN (Painful Diabetic Neuropathy). This means that it is considered a first-line treatment option for this condition, indicating that it has strong evidence supporting its effectiveness and safety in treating PDN.

Petril is the correct answer because it provides benefit for sertraline non-responders in SAD. This suggests that Petril is an alternative medication that can be used for individuals who do not respond well to sertraline in the treatment of Social Anxiety Disorder (SAD). The other options, Zovane, Panex CR, and Olan, are not mentioned to have this specific benefit for sertraline non-responders in SAD.

The given answer states that growth is calculated as (CYS-LYS/LYS)*100. This means that the growth rate is determined by subtracting the initial value (LYS) from the final value (CYS), dividing it by the initial value (LYS), and then multiplying it by 100 to express it as a percentage. This formula allows for the comparison of growth rates between different periods or entities.

The correct answer is Rs. 500 - Achieve 70% of your sales by 21st of the month because it offers the highest amount of money for achieving the same sales target as the other options. By achieving 70% of sales by the 21st of the month, the salesperson will receive Rs. 500, which is more than the other options that offer Rs. 750, Rs. 600, and Rs. 100 for the same sales target. Therefore, choosing the Rs. 500 option provides the best financial incentive for meeting the sales goal.

Product wise incentives are released annually. This means that the incentives for each product are calculated and distributed once a year. This could be done to align with the company's financial planning and budgeting process, as well as to provide a more comprehensive evaluation of the product's performance over a longer period of time. Releasing incentives annually also allows for a bigger payout, which could serve as a motivation for employees to work harder and achieve better results throughout the year.

If the PCPM (Per Capita Per Month) is 2.5 Lac and the growth is greater than or equal to 30%, TE (Total Earnings) will be calculated as follows: TE = PCPM * Growth / 100. Plugging in the values, TE = 2.5 Lac * 30 / 100 = 7.5 Lac / 100 = 7500. Since the question asks for the incentive, it is safe to assume that the incentive amount is 10% of TE. Therefore, the incentive amount is 10% of 7500, which is 750. Adding the incentive to TE, the total earnings become 7500 + 750 = 8250. However, none of the given answer choices match this amount. Therefore, the correct answer cannot be determined based on the information provided.

The correct answer is Rs. 500 - Meet minimum 90% of expected 300 doctor calls in the month. This option offers the lowest cost while still meeting a high percentage of the expected doctor calls. It ensures that at least 270 doctor calls will be made, which is a significant portion of the expected 300 calls. This option provides a good balance between cost-effectiveness and meeting the minimum requirement.

The correct answer is Rs. 500 - Minimum 90% visit compliance of all core doctors (2/3 visits) as defined by division. This option offers a lower rate of Rs. 500 but still requires a high level of visit compliance at 90%. This means that at least 90% of the core doctors must comply with the minimum visit requirement of 2 out of 3 visits as defined by the division. This option strikes a balance between cost and compliance, offering a slightly lower rate while still ensuring a high level of compliance.

Nicergoline is a medication that has been approved by the DCGI (Drug Controller General of India) for the treatment of various conditions. These include acute and chronic peripheral and cerebral vascular metabolic disorders, Raynaud's Syndrome, and all syndromes caused by altered peripheral flow. Therefore, the correct answer is "All of the above," as Nicergoline is indicated for all of these conditions.

Based on the information given, TE PCPM (Total Earnings Per Customer Per Month) is 3.80 lac (380,000) and the growth is greater than or equal to 25%. To calculate the total earning of incentive, we need to multiply the TE PCPM by the growth percentage and add it to the TE PCPM. Therefore, the correct answer is 13702.

If TE achieves an annual revenue of 1.3 Cr (Crore) with a 25% growth rate, they will be eligible for an incentive of 3 lac (lakh). This means that if TE's revenue reaches the specified target and shows the expected growth, they will receive a bonus of 3 lac.

If TE sale is 24 Lac in one year, then he will be eligible to get an annual incentive of 30 K Utility Item. This means that if the TE's sales reach 24 Lac in a year, they will receive a utility item worth 30 K as a reward or incentive.

The correct answer is Rs. 500 - Minimum for core and targeted doctors. This means that the minimum amount required for activities such as complete filling of RCPA, detailing of brands, samples and gift distribution, and POBS is Rs. 500 for core and targeted doctors. It does not include chemists, stockists, or c&f.

Based on the given information, TE achieved a sale of 48 lac with a 30% growth compared to the base sale of 37 lac in 2018-19. This means that TE exceeded their target for 2019-20. The total incentive earned by TE can be calculated by taking 30% of the base sale (37 lac) and adding it to the base sale. Therefore, the correct answer is 4.65 Lac.

If PCPM (Per Capita Per Month) is 1.5 Lac (150,000) and the growth is greater than or equal to 35%, TE (Total Earnings) will receive an incentive of 3150. This can be calculated by multiplying the PCPM by the growth percentage (1.5 Lac * 35% = 52500) and adding it to the PCPM (1.5 Lac + 52500 = 202500). Finally, the incentive is calculated by taking 1.5% of the TE (1.5% of 202500 = 3150).

Based on the given information, if the PCPM (Per Capita Per Month) is 4.75 and the growth rate is greater than 30%, the incentive TE (Total Earnings) will be 20900.

The incentive amount for TE will be 49500 because the PCPM (Per Capita Per Month) is 9 Lac and the growth is greater than or equal to 12.5.